What is the 13F Pro Quality Score for PHAT?

13F Pro ranks Phathom Pharmaceuticals, Inc. (PHAT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PHAT's current score at https://13fpro.ai/research/PHAT (free sign-up required for the full ranking).

Where does 13F Pro source PHAT data?

All Phathom Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Phathom Pharmaceuticals, Inc. files with the SEC under CIK 1783183. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PHAT in?

Phathom Pharmaceuticals, Inc. (PHAT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PHAT research updated on 13F Pro?

PHAT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Phathom Pharmaceuticals, Inc.(PHAT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1783183 PHAT stock profile & AI dashboard →

13F Pro Quality Score

32.5/100

Rank #2,264 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.1/100

Profitability

6.5/100

Balance Sheet

0.9/100

Earnings Quality

30.0/100

Free Cash Flow

6.8/100

Institutional Flow

93.6/100

Revenue Scale

22.9/100

Dilution Risk

11.5/100

PHAT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Phathom Pharmaceuticals, Inc. (PHAT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PHAT at 32.5/100 on a 32-signal composite quality model, placing it at rank #2,264 of 2,879 stocks — the bottom half of the AI-ranked universe. PHAT scores in the top quartile across revenue growth (99.1), institutional flow (93.6). Areas of concern include balance sheet strength (0.9) and profitability (6.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Phathom Pharmaceuticals, Inc. reports quarterly revenue of $58.3M, net income of $-30.4M, free cash flow of $-15.7M. Top institutional holders of PHAT by reported 13-F value include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Invesco Ltd., based on the most recent SEC filings. PHAT trades on the Nasdaq exchange and files with the SEC under CIK 1783183. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Phathom Pharmaceuticals, Inc. directly from SEC EDGAR. Phathom Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 8 and 38 since 2024, currently 32.5 — an improving long-term trajectory across 44 quarterly and live scoring snapshots.

✦

Fun facts about Phathom Pharmaceuticals, Inc.

Quirks, history, and lore behind PHAT — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in North Carolina · focused on gastrointestinal diseases.
2
The Numbers
A relatively small-cap company with limited commercial revenue as it advances its pipeline — typical of a late-stage pharma firm still chasing its first major approval.
3
The History
Founded around 2018 as a spinout focused on licensing and developing compounds targeting acid-related GI conditions, giving it a narrow but deep therapeutic focus from day one.
4
The Secret
Its lead program targets gastroesophageal reflux disease and erosive esophagitis — a market dominated by decades-old blockbusters that this company believes it can disrupt with a next-generation approach.
5
The Lore
The company was built around a potassium-competitive acid blocker licensed from Takeda Pharmaceutical — essentially betting the whole house on one promising mechanism.
6
The Giveaway
Its flagship drug vonoprazan earned FDA approval for erosive GERD, and its ticker — a cheeky PHAT — might be the most memorable four letters in pharma.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$58.3M

Net Income

Q1 2026

$-30.4M

Free Cash Flow

Q1 2026

$-15.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+216.9% YoY

$175.1MFY 2025

FY21 —FY23 $682.0KFY24 $55.3MFY25 $175.1M

Net Income

+33.8% YoY

$-221.3KFY 2025

FY21 $-143.9MFY23 $-201.6MFY24 $-334.3KFY25 $-221.3K

Operating Income

+42.3% YoY

$-160.0MFY 2025

FY21 $-135.1MFY23 $-167.3MFY24 $-277.5MFY25 $-160.0M

EPS (Diluted)

+42.7% YoY

$-3.03FY 2025

FY21 $-3.89FY23 $-3.93FY24 $-5.29FY25 $-3.03

Total Assets

-31.5% YoY

$259.1MFY 2025

FY21 $189.4MFY23 $413.8MFY24 $378.3MFY25 $259.1M

Total Debt

+3.8% YoY

$209.1MFY 2025

FY21 $89.7MFY23 $137.8MFY24 $201.4MFY25 $209.1M

Op. Cash Flow

+37.5% YoY

$-166.8MFY 2025

FY21 $-148.5MFY23 $-137.6MFY24 $-266.8MFY25 $-166.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2017
Revenue	$175.1M +216.9%	$55.3M +8001.5%	$682.0K	—	—	—
Net Income	$-221.3K +33.8%	$-334.3K +99.8%	$-201.6M -40.1%	$-143.9M -11.5%	$-129.1M	—
Operating Income	$-160.0M +42.3%	$-277.5M -65.8%	$-167.3M -23.9%	$-135.1M -7.5%	$-125.7M	—
EPS (Diluted)	$-3.03 +42.7%	$-5.29 -34.6%	$-3.93 -1.0%	$-3.89	—	—
Total Assets	$259.1M -31.5%	$378.3M -8.6%	$413.8M +118.5%	$189.4M -35.8%	$295.1M	—
Total Debt	$209.1M +3.8%	$201.4M +46.1%	$137.8M +53.7%	$89.7M +65.0%	$54.3M	—
Operating Cash Flow	$-166.8M +37.5%	$-266.8M -93.9%	$-137.6M +7.3%	$-148.5M -113.0%	$-69.7M	—

Get alerted when PHAT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Phathom Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PHAT

Frazier Life Sciences Management, L.P.
$138.5M12,466,489 sh
Medicxi Ventures Management (Jersey) Ltd
$82.9M7,464,572 sh
Invesco Ltd.
$48.0M4,322,060 sh
BlackRock, Inc.
$45.1M4,061,996 sh
MILLENNIUM MANAGEMENT LLC
$44.7M4,022,909 sh
Carlyle Group Inc.
$38.8M3,496,808 sh
VANGUARD CAPITAL MANAGEMENT LLC
$28.7M2,583,636 sh
NEA Management Company, LLC
$21.8M1,960,169 sh
683 Capital Management, LLC
$20.6M1,850,000 sh
Ensign Peak Advisors, Inc
$18.1M1,627,806 sh

Fund	Value	Shares
Frazier Life Sciences Management, L.P.	$138.5M	12,466,489
Medicxi Ventures Management (Jersey) Ltd	$82.9M	7,464,572
Invesco Ltd.	$48.0M	4,322,060
BlackRock, Inc.	$45.1M	4,061,996
MILLENNIUM MANAGEMENT LLC	$44.7M	4,022,909
Carlyle Group Inc.	$38.8M	3,496,808
VANGUARD CAPITAL MANAGEMENT LLC	$28.7M	2,583,636
NEA Management Company, LLC	$21.8M	1,960,169
683 Capital Management, LLC	$20.6M	1,850,000
Ensign Peak Advisors, Inc	$18.1M	1,627,806

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PHAT on your watchlist

Track score changes the day Phathom Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PHAT a good stock to buy?

13F Pro's AI-powered analysis of Phathom Pharmaceuticals, Inc. (PHAT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PHAT are available on the PHAT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PHAT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PHAT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Phathom Pharmaceuticals, Inc.'s investment landscape.